Aemetis Inc. (AMTX) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, AMTX carries an RQD Score of 28 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars score as follows: Fundamental Cash Engine 9/20 (ROIC -35%; FCF yield -24.42%), Whale 13F Flow 3/20, Insider Conviction 3/20, Macro Regime Fit 5/20 (Beta 1.0), and Forensic Balance Sheet 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). Every pillar sits well below its 20-point maximum. The weakest signals are institutional and insider positioning, which are the pillars that would ordinarily corroborate a thesis from outside the company; the cash-engine pillar is also depressed by negative returns on capital and negative free cash flow yield. For a prospective investor evaluating the stock today, the rating frames the setup as one where the reported economics and the ownership signals both point away from the stock, with the balance sheet scored as a forensic concern rather than a strength. Upside drivers would need to come from outside the rated data, and the source data does not establish any such driver. The rating is an analytical summary of the supplied figures and is not personalized financial advice.

Aemetis Inc. (AMTX) is a NASDAQ-listed issuer classified in the Materials sector and the Major Chemicals industry, per the profile section. The source data does not describe its specific products, customers, or revenue model beyond the sector and industry classification. The reported revenue figures (see Financial Trend) are the only operating disclosure available, and they are not broken down by product or customer in the source data.

Per the market data, gross margin is -0.4%, operating margin -17.9%, and net margin -37%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported net losses appear in all three periods, and free cash flow was negative in FY 2025 and FY 2024 after a positive figure in FY 2023. Debt in the source data declined from $247.5M in FY 2024 to $63.9M in FY 2025, while reported cash was $4.9M at FY 2025.

Per the recent news section, the wire items reference a biogas digester start-up ("Aemetis Begins Operation of Two New Biogas Digesters"), a weekly recap citing "$22.8M 45Z credits and Keyes RNG station," a Q3'26 earnings revenue estimate of 74.20M USD, and two MarketBeat items reporting the stock price breaking below its 200-day moving average. All items are tagged with a YELLOW light and MARKET WIRE impact label. The source data does not provide the content of these reports beyond their headlines and summaries, so their substance cannot be confirmed. Risk watch items include the sub-200-day moving average crossovers and the negative reported margins. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, sector correlations, or proprietary signal links are recorded. The source data therefore does not establish any 2nd-order ripple effects. A prospective investor should note the absence of mapped supply-chain links as a gap in the analysis rather than as evidence of independence.

• What are the specific products, customers, and revenue drivers behind the reported FY 2024 and FY 2025 revenue figures?
• What is the basis for the reported cash of $4.9M against debt of $63.9M in FY 2025, and what is the debt maturity profile?
• What drove the decline in reported debt from $247.5M to $63.9M between FY 2024 and FY 2025?
• What are the content and financial implications of the 45Z credits and biogas digester news referenced in the wire?
• Why are EPS, P/E, and forward estimates unavailable, and what is the current share count?